While the translation of our results to HIV infection in vivo is complex, and many aspects about the weight of the possible PD-1/PD-L1 roles for HIV expansion at different anatomical sites are not completely defined, the upcoming clinical trials will definitely increase our knowledge on Treg cell biology and provide a clear picture on the pros and cons of immune checkpoint modification in HIV infection. The gene discussed is PDCD1; the disease is HIV infectious disease.